These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 34250395)

  • 1. Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.
    Moaven O; Mangieri CW; Stauffer JA; Anastasiadis PZ; Borad MJ
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspectives on Vaxinia virus: an immuno-oncolytic vector in cancer therapy.
    Kaur SD; Singh AD; Kapoor DN
    Med Oncol; 2023 Jun; 40(7):205. PubMed ID: 37318642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
    De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
    Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic viruses & their specific targeting to tumour cells.
    Singh PK; Doley J; Kumar GR; Sahoo AP; Tiwari AK
    Indian J Med Res; 2012 Oct; 136(4):571-84. PubMed ID: 23168697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice.
    Moaven O; W Mangieri C; A Stauffer J; Anastasiadis PZ; Borad MJ
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses.
    Bifulco M; Di Zazzo E; Napolitano F; Malfitano AM; Portella G
    Biochimie; 2023 Mar; 206():89-92. PubMed ID: 36273765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viruses as nanomedicine for cancer.
    Badrinath N; Heo J; Yoo SY
    Int J Nanomedicine; 2016; 11():4835-4847. PubMed ID: 27703350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in targeting cancer stem cells using oncolytic viruses.
    Zhang YN; Wang SB; Song SS; Hu PY; Zhou YC; Mou YP; Mou XZ
    Biotechnol Lett; 2020 Jun; 42(6):865-874. PubMed ID: 32166558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making Oncolytic Virotherapy a Clinical Reality: The European Contribution.
    Duffy MR; Fisher KD; Seymour LW
    Hum Gene Ther; 2017 Nov; 28(11):1033-1046. PubMed ID: 28793793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Virus-Driven Biotherapies from Bench to Bedside.
    Duan S; Wang S; Qiao L; Yu X; Wang N; Chen L; Zhang X; Zhao X; Liu H; Wang T; Wu Y; Li N; Liu F
    Small; 2023 Jun; 19(23):e2206948. PubMed ID: 36879416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.
    Guo ZS; Thorne SH; Bartlett DL
    Biochim Biophys Acta; 2008 Apr; 1785(2):217-31. PubMed ID: 18328829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy.
    Phan M; Watson MF; Alain T; Diallo JS
    ACS Infect Dis; 2018 Oct; 4(10):1448-1467. PubMed ID: 30152676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour vasculature: Friend or foe of oncolytic viruses?
    Santry LA; van Vloten JP; Knapp JP; Matuszewska K; McAusland TM; Minott JA; Mould RC; Stegelmeier AA; Major PP; Wootton SK; Petrik JJ; Bridle BW
    Cytokine Growth Factor Rev; 2020 Dec; 56():69-82. PubMed ID: 32893095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of oncolytic viruses.
    Sanjuán R; Grdzelishvili VZ
    Curr Opin Virol; 2015 Aug; 13():1-5. PubMed ID: 25699475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.